Pharming Group NV (PHAR) — Capital Reinvestment Ratio
Pharming Group NV (PHAR) has a Capital Reinvestment Ratio of 0.15x as of March 2026, meaning it reinvests 0% of its operating cash flow ($1.63 Million) in capital expenditures ($238.86K). Check PHAR intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Pharming Group NV Capital Reinvestment Ratio (2017–2025)
This chart tracks Pharming Group NV's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see PHAR operating cash flow.
Annual Capital Reinvestment Ratio for Pharming Group NV (2017–2025)
Year-by-year Capital Reinvestment Ratio for Pharming Group NV from 2017 to 2025. See PHAR free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.02x | $50.07 Million | $751.09K | ▼ -83.0% |
| 2022 | 0.09x | $22.46 Million | $1.98 Million | ▼ -80.1% |
| 2021 | 0.44x | $37.84 Million | $16.72 Million | ▲ +141.4% |
| 2020 | 0.18x | $83.63 Million | $15.30 Million | ▼ -46.7% |
| 2019 | 0.34x | $74.15 Million | $25.45 Million | ▲ +267.7% |
| 2018 | 0.09x | $46.19 Million | $4.31 Million | ▼ -41.0% |
| 2017 | 0.16x | $45.84 Million | $7.25 Million | — |